Clinical Trial Update: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the combination of ipilimumab and rituximab in relapsed or refractory CD20-positive B-cell no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED